TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:42
CEL SCI CORP ( CVM ) https://cel-sci.com
1.88USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-18.26%
CVM
SPY
32.74%
-88.56%
CVM
SPY
92.93%
-46.89%
CVM
SPY
224.41%
-95.12%
CVM
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
94.54
96.31
0.48
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.96
-160.73
7.47
-25.79
0.00
-3.56
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
11.1332
-73.00
-81.51
1.84
Other Earnings and Cash Flow Stats:
CEL SCI CORP ( CVM ) Net Income TTM ($MM) is -31.99
CEL SCI CORP ( CVM ) Operating Income TTM ($MM) is -30.49
CEL SCI CORP ( CVM ) Owners' Earnings Annual ($MM) is -176.69
CEL SCI CORP ( CVM ) Current Price to Owners' Earnings ratio is -0.53
CEL SCI CORP ( CVM ) EBITDA TTM ($MM) is -26.59
CEL SCI CORP ( CVM ) EBITDA Margin is 0.00%
Capital Allocation:
CEL SCI CORP ( CVM ) has paid 0.00 dividends per share and bought back -5.578214 million shares in the past 12 months
CEL SCI CORP ( CVM ) has reduced its debt by 26.172454 million USD in the last 12 months
Capital Structure:
CEL SCI CORP ( CVM ) Interest-bearing Debt ($MM) as of last quarter is 1
CEL SCI CORP ( CVM ) Annual Working Capital Investments ($MM) are 2
CEL SCI CORP ( CVM ) Book Value ($MM) as of last quarter is 12
CEL SCI CORP ( CVM ) Debt/Capital as of last quarter is 14%
Other Balance Sheet Stats:
CEL SCI CORP ( CVM ) has 5 million in cash on hand as of last quarter
CEL SCI CORP ( CVM ) has 4 million of liabilities due within 12 months, and long term debt 10 as of last quarter
CEL SCI CORP ( CVM ) has 50 common shares outstanding as of last quarter
CEL SCI CORP ( CVM ) has 0 million USD of preferred stock value
Academic Scores:
CEL SCI CORP ( CVM ) Altman Z-Score is -24.06 as of last quarter
CEL SCI CORP ( CVM ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
CEL SCI CORP ( CVM ) largest shareholder is Sio Capital Management, LLC owning 695700 shares at 1.31 ($MM) value
PRICHEP PATRICIA B(Senior Vice President) Bought 1091 shares of CEL SCI CORP ( CVM ) for the amount of $4287.63 on 2022-03-31
3.43% of CEL SCI CORP ( CVM ) is held by insiders, and 11.10% is held by institutions
CEL SCI CORP ( CVM ) went public on 1987-01-01
Other CEL SCI CORP ( CVM ) financial metrics:
FCF:-23.16
Unlevered Free Cash Flow:-31.06
EPS:-0.54
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-212.15
Beta:1.84
Buffet's Owners Earnings:-176.69
Price to Owner's Earnings:-0.53
About CEL SCI CORP ( CVM ) :
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 product candidates for the treatment of rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.